The Therapeutic Use of Impella Device in Cardiogenic Shock: A Systematic Review

Carlos Munoz Tello, Dawood Jamil, Hadrian Hoang-Vu Tran, Mafaz Mansoor, Samia Rauf Butt, Travis Satharine, Pranuthi Ratna, Aditi Sarker, Adarsh Srinivas Ramesh, Lubna Mohammed

Abstract

Impella (Abiomed, Danvers, MA) devices nowadays have been linked to cardiogenic shock (CS) due to the importance of their use as therapeutic instruments. This study aims to review pathophysiologic mechanisms of cardiogenic shock and the implementation of Impella to overcome this condition. To investigate several different types of studies and analyze the use of Impella device in cardiogenic shock and the outcomes of heart malfunctioning and determine its positive and negative impacts as a therapeutic tool in cardiac ischemia and use as a resource in critical patients, we conducted a systematic review through different databases (PubMed, ScienceDirect, and Google Scholar) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and used the Medical Subjects Heading (MeSH) search strategy to obtain significant articles. We found 883 papers in total, and after removing duplicates, applying inclusion/exclusion criteria, and finding the most significant information, we ended up with 30 articles that were reviewed containing information about the impact of Impella device in cardiogenic shock in different locations. The study strongly concludes that Impella device in the setting of cardiogenic shock has more advantages than disadvantages in terms of outcomes and complications as a non-pharmacologic tool. Improvements in left ventricular ejection fraction and signs and symptoms of cardiogenic shock criteria were determinants. Nevertheless, complications during the implementation and use of the device were established; in this manner, the evaluation and treatment of each patient separately are imperative. Consequently, more studies on this relevant topic are needed.

Introduction And Background

Cardiogenic shock (CS) is one of the most common complications and the leading cause of death in patients with a diagnosis of cardiac ischemia. The left coronary artery that supplies most of the left ventricle is the most frequently affected artery, which leads to left heart failure and subsequently right heart failure. The pump's exhaustion due to cardiac insults provokes the left ventricular diastolic and systolic pressures to compensate improperly. As a result, there is low circulation and oxygen supply to the cardiac cells, affecting the stroke volume. This increases the venous pressure backward and overpowers the pulmonary circulation. In addition to these events, the cardiac output is insufficient while supplying blood, oxygen, and nutrients to the tissues, which leads to end-organ hypoperfusion, systemic vasoconstriction, and generalized hypoxia [1,2].

CS criteria are defined by systolic blood pressure (SBP) of <90 mmHg for more than 30 minutes or supportive intervention to preserve the systolic pressure when it is >90 mmHg, in addition to the evidence of organ failure (mental impairment, urine output of <30 ml/hour, or cold extremities) [3]. The frequency of CS is 5%-10% in acute cardiac ischemia and has increased twofold between 2004 and 2014. The mortality associated with this condition is around 50% in patients with acute myocardial infarction (AMI) [1,4,5].

Currently, coronary revascularization and the use of inotropes are the principal keys to approaching AMI associated with CS [1]. Although clinical and interventional treatment is a tool for this scenario and is established as part of the guidelines, the management is sometimes not enough to meet the needs of a patient with AMI complicated with CS. For that reason, some devices can be used in this situation, such as the intra-aortic balloon pump (IABP), the left atrial-femoral artery bypass (TandemHeart, LivaNova, Houston, TX), the veno-arterial extracorporeal membrane oxygenation (VA-ECMO), and the Impella (Abiomed, Danvers, MA) device [6].

The Impella device is a tool that is increasingly used to provide mechanical support when there is heart failure provoked by an AMI [7]. This device consists of a microaxial pump that crosses the aortic valve

Categories: Cardiology, Emergency Medicine, Internal Medicine
Keywords: cardiovascular intervention, heart assist devices, heart failure, impella device, cardiogenic shock
toward the left cavity of the ventricle. It continuously extracts blood from the left cavity and unloads it into the arterial circulation, improving circulation, preventing systemic hypotension and tissue hypofunction, and decreasing the severity of the complications. However, some factors, such as age and lactate levels, could be decisive in their use [8,9].

Nowadays, the use of these appliances in the heart scenarios mentioned above has increased. The aim of interventional cardiology has rapidly and favorably changed. Even though some studies on the outcomes of using Impella devices in CS already exist, science must constantly update the information and integrate these devices into management to gain a better understanding of the effects in serious conditions such as CS. Given this, there are currently more research studies being conducted regarding this topic, and as evidence emerges, new mechanisms or protocols can be modified in order to deeply understand their uses in cardiology. In this systematic review, we seek to analyze various study results from the application of the Impella device to collect information on cardiovascular disease. Figure 1 illustrates the pathophysiology of CS.

**FIGURE 1: Pathophysiology of cardiogenic shock**

### Methods

We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist [10]. As secondary data from published articles were used, ethical approval was not taken into consideration.

### Search strategy

PubMed, ScienceDirect, and Google Scholar were used as databases to find relevant studies. We selected articles published in the last five years. We applied the Medical Subject Heading (MeSH) search strategy to obtain related articles and also keywords to find the appropriate information for ‘Impella Device in Cardiogenic Shock.’

Keywords such as Impella device, cardiogenic shock, and heart assist device were used in conjunction with the MeSH strategy. Furthermore, Booleans such as ‘AND’ and ‘OR’ were utilized to connect the different terms mentioned above. Table 1 is a summary of the search strategy for this systematic review.
Inclusion criteria
We have included articles written in English in the last five years and peer-reviewed, studies done in humans, and all types of studies and settings. We focused this research on the intervention of the Impella device in cardiogenic shock in patients who are 65+ years old.

Exclusion criteria
We did not include articles written in languages other than English, studies done in animals or in patients younger than 65 years old, gray literature, unpublished articles, or articles done before 2017. Population, intervention, comparison, and outcomes (PICO) criteria were used as a framework for our eligibility criteria.

Data selection and extraction
Two researchers decided to select and extract studies related to the topic. The researchers resolved this systematic review step by step and discussed different study designs and outcomes and the inclusion and exclusion criteria for screening and assortment. If there was an inconclusive article, both would analyze it and take a decision after asking the third and fourth author.

Through the three databases, 877 articles were selected after the removal of duplicates by EndNote (Clarivate, Philadelphia, PA) software. We applied the inclusion and exclusion criteria with the search strategy at the beginning of the screening and identified articles directly related to the topic. The researchers analyzed the articles during the screening process, and a total of 30 articles were selected.

Quality assessment
The studies selected by two independent researchers were qualified to decrease the probability of bias and to ensure proper selection and high-quality scores. Clinical trials were evaluated using the Cochrane risk of bias assessment tool (RoB 2). Observational studies (case-control and cohort) were assessed by the Newcastle-Ottawa scale, case report/series by Case Report (CARE) guideline checklist, and systematic review/meta-analysis by Assessing the Methodological Quality of Systematic (AMSTAR) checklist. Every paper was reviewed using the previously mentioned quality assessment tools, and those with an average quality score of more than 75% were selected.

Results
Using different methods across the databases, we found 877 records in total. Three hundred thirty-eight of them were found in ScienceDirect, 523 in PubMed, and 22 in Google Scholar. Before the screening and selection of the studies, we manually removed six duplicates. The 877 articles were thoroughly assessed for relevance in their titles and abstracts. As a result, we were able to exclude 834 articles due to their lack of relevance regarding the topic, aims, and inclusion and exclusion criteria. The PRISMA guidelines were followed, and they are exhibited in Figure 2 [10].
Therefore, 43 articles were sought for retrieval, and after going through all of them, we further removed 10 studies. We assessed 33 articles for eligibility, and three articles did not achieve the quality appraisal required and thus were excluded. Table 2 [6,8,9,11-37] contains the details of the relevant 30 articles included.

| Author and year | Type of study | Patient age | Purpose of the study | Results | Conclusion |
|-----------------|---------------|-------------|----------------------|---------|------------|
| 1 Abdullah et al., 2021 [9] | Cohort | 69.0±18.0 years | The evaluation of results and prognosticators in a real-world scenario by the Impella device in CS. | At baseline, lactate levels were 4.7 mmol/L, and the mortality rate was 81%. Age and lactate were related to mortality. | Age and lactate help in the selection for Impella placement because mortality is high in sick CS patients. |
| 2 Afara et al., 2021 [6] | Case series | 29-69 years, mean of 55.5 years | Transcaval access route as an alternative for peripheral Impella application in CS. | Due to the challenging peripheral entry, 10 patients underwent the Impella 5.0 device placement procedure successfully in CS by transcaval access. | Transcaval access was a successful method for the insertion of emergency mechanical cardiac support when peripheral access was inadequate. |
| 3 Ashraf et al., 2020 [11] | Case report | 70 years | A patient with mitral regurgitation and an acute myocardial infarction (AMI) was treated with percutaneous coronary intervention, a stent, and Impella support. | After experiencing Impella support, percutaneous coronary intervention, and a stent placement for acute mitral regurgitation associated with an AMI, the patient regained hemodynamic stability and showed clinical improvement at one-month follow-up. | The Impella Cardiac Power Pump associated with MitraClip (Abbott Laboratories, Chicago, IL) repair was successful and secure in this patient. |
| No. | Authors et al., Year | Study Type | Participants | Summary |
|-----|----------------------|------------|--------------|---------|
| 4   | Adkins et al., 2020  | Case report| 70 years     | Report on a case management with a Takotsubo syndrome diagnosis complicated by severe mitral regurgitation. A patient with left ventricular outflow tract obstruction and severe mitral regurgitation assisted by the Impella device was discharged after one week in stable conditions. The Impella device is suggested as being an appropriate implement for patient recovery. |
| 5   | Boshlah et al., 2020  | Prospective randomized trial | 90.3±12.3 years | Twelve patients available out of fifteen with acute myocardial infarction and CS treated with inotropes and intra-arterial balloon pumps (IABP) were evaluated besides adding the Impella device. The cardiac power index showed no substantial difference between 12 and 66 hours. In both groups, the left ventricular ejection fraction was similar at baseline and after one month. The rate of bleeding was high and common. In patients with an AMI and CS, treatment with vasopressors, an intra-arterial balloon pump, and a combination with Impella did not improve left ventricular ejection fraction during the initial phase of treatment on one month later. Combining them all together could be harmful. |
| 6   | Buscetta et al., 2019 | Cohort | 72±10 years | A report on Impella device placement as a protective tool for highly risky patients. At 12 months, patient mortality was 10.5%. In those, left ventricular ejection fraction improved by 105%, compared to 22% before Impella-protected percutaneous coronary intervention. In complicated and high-risk patients, the Impella device placement was maintained for protected percutaneous coronary intervention. Improved left ventricular ejection fraction outcomes and advanced percutaneous coronary intervention were associated. |
| 7   | Chinoura et al., 2021 | Cross-sectional | Mean of 65.4 years | Observe trends in the application of mechanical cardiac support in patients treated for AMI with CS with percutaneous intervention. Intravascular microcirculatory left ventricular assist device usage increased (4.1%–10.0%), while IABP usage decreased (34.8%–30.0%). In this study, a 2.5-fold increase in intravascular microcirculatory left ventricular assist devices and a decrease in IABP placement were seen as a trend. |
| 8   | Chau et al., 2018 | Cohort | Male: 61.4±13.1; Female: 67.3±15.1 | A report on patient gender variance in the setting of CS in short-term survival and in-hospital outcomes after experiencing percutaneous coronary intervention with the Impella association. In terms of survival after 30 days, there was no difference between the gender groups. Additionally, in both groups, the outcomes were improved by starting Impella prior to a percutaneous coronary intervention. Gender differences were not observed to be different, and mechanical cardiac assistance may improve survival and reduce problems in both sexes. |
| 9   | Elder et al., 2018 | Case series | 50±22 years | A report on patients with acute pulmonary embolism (PE) in shock with proof of hemodynamic instability underlying the Impella device. There were five cases of pulmonary embolism associated with shock. The cardiac index increased from a mean of 1.68 L/min/m² to 2.5 L/min/m² in 24 hours. No other complications were found. The Impella device demonstrated hemodynamic improvement, correcting pulmonary embolism-induced shock, and increasing patient survival. |
| 10  | Elder et al., 2018 | Case report | 65 years | A report on a case of a left ventricular Impella (BP) support in a patient with refractory out-of-hospital cardiac arrest. Impella showed improvement in right ventricle function, whereas the left ventricle had no changes. Twelve months later, the patient was in good condition. A patient who had refractory out-of-hospital cardiac arrest was successfully treated with biventricular Impella support. |
| 11  | Raffel et al., 2017 | Case series | 60±11 years | Twenty-two patients maintained by the Impella device (17 patients with CS) were investigated for acquired von Willebrand syndrome. The presence of acquired von Willebrand syndrome was found in 95% of the patients. A frequent concern when using the Impella device to support the left ventricle is acquired von Willebrand syndrome. It could be the cause of bleeding problems in patients at high risk. |
| 12  | Goldfarb et al., 2016 | Case series | 57.5±13.7 years | A report on patients assessed to demonstrate coagulation problems (von Willebrand syndrome) related to mechanical cardiac support. Von-Willebrand syndrome workup was recommended for 10 patients with mucosal bleeding (50%) and a drop in hemoglobin level (35%). Specifically, the type 1 von Willebrand qualitative defect is consistent with all reported cases of high or normal low molecular-weight multimers. Temporary mechanical cardiac support devices were associated with the loss of high-molecular-weight multimers. When receiving short-term mechanical circulatory support, these findings may have implications for any future interventions or heart transplants. |
| 13  | Hemanaraka et al., 2020 | Case report | 70 years | A report on a case management during microcirculation in patients with ST-elevation myocardial infarction. The Impella device increased coronary flow and decreased the index of microcirculatory resistance through the use of Pselectin (p<0.05) Vascular, Santa Clara, CA. Myocardium was found to be exempt of acute damage by cardiac magnetic resonance. This case indicates that the Impella device improves coronary microcirculation by unloadng the left ventricle, lowering endocardial pressure, and subsequently lowering coronary microcirculatory resistance. |
| 14  | Hasegawa et al., 2021 | Case report | 66 years | A report on a case report on a patient with AMI, CS, electric storm, and difficult peripheral access who was treated with Impella via the left axillary, the removal of the IABP, and ventricular pacing. The Impella device combined with atrial overdrive pacing with difficult peripheral access, CS, and electric storm was successfully effective. Alternative artery access for the Impella device was not needed. |
| 15  | Hritani et al., 2019 | Cohort | Median of 74 years | The evaluation of outcomes with Impella device placement at 30 days in the United States. Forty-four patients were evaluated; 27 were in high-risk percutaneous coronary intervention, and 17 were in CS. CS mortality in 30 days was 76.9% and in the high-risk percutaneous coronary intervention 11.1%. Renal dysfunction was the most common complication. Despite the theoretical use of the Impella device, the outcome in CS continues to be poor. |
| 16  | Isomaccone et al., 2021 | Meta-analyses | Median age of 61.9 years | Outcomes of hemodynamic support with the Impella device. Seventeen studies were analyzed with 3833 patients. CS-related myocardial infarction was 79.6%. The 30-day mortality was 47.8%. Based on meta-regression analysis, the Impella 5.0 and Impella Cardiac Power were related to a higher survival rate. Prior percutaneous coronary intervention with no cardiac arrest using the Impella device was recommended with better outcomes, but at 30 days, Impella-treated mortality in CS is still high. |

| 17  | Explore the capability and outcomes of the Impella device. | |
| 18  | The Impella 2.5 assistance in tolerating percutaneous coronary intervention was maintained for protected percutaneous coronary intervention. Improved left ventricular ejection fraction outcomes and advanced percutaneous coronary intervention were associated. | |
| Lastname et al., 2020 | Case series | Mean age (61±13) years | The evaluation of left ventricle assistance with the Impella device on the renal function by Doppler ultrasonography in CS. | The Impella device was used for left ventricular support in patients with ischemic CS. Twenty-five patients with non-ischemic CS were compared to 50 patients with ischemic CS. No difference was established in both groups at 30-day survival and in hospital mortality. As a result, showing similarities in terms of treatment use. | In both ischemic and non-ischemic CS, temporary Impella device therapy has been proposed as a bridge to recovery. |
|---|---|---|---|---|---|
| Meraj et al., 2017 | Case series | Mean of 69±4.2 years | A report on four patients with Takotsubo syndrome complicated by CS rescues without the Impella device. | Three out of four patients who presented with an increase in left ventricular end-diastolic pressure were helped by the Impella device support during resuscitation. | In a patient with Takotsubo syndrome complicated by CS, the Impella device support contributed to an improvement in the cardiac index. |
| Oktur et al., 2018 | Case series | Mean age (61±9.7) years | The evaluation of laboratory numbers could help determine the risk of hemorrhage complications. | Thirty-two (53.3%) patients showed major or fatal bleeding complications, despite heparin use to maintain normal activated partial thromboplastin time. In this study, bleeding was associated with acquired von Willebrand syndrome. | Acquired von Willebrand syndrome was associated with bleeding complications, and activated partial thromboplastin time monitoring was unsatisfactory to prevent these events. A patient with an Impella device should have their anticoagulation better assessed. |
| Pappasotiropoulos et al., 2017 | Case control | Mean age (68±5) years | Compare the outcomes of patients with CS and non-CS who received VA-ECMO and Impella to those who received only VA-ECMO. | Patients with VA-ECMO and Impella had an inferior hospital mortality rate of 47% versus 80% for VA-ECMO only. The road to recovery was higher with additional therapy (48% versus 28%) compared with VA-ECMO. | Compared to VA-ECMO alone, VA-ECMO-combined with Impella may improve outcomes in patients with CS. |
| Pari et al., 2017 | Case series | Mean age of 61±10 years | Define the function of the axillary Impella devices in the setting of CS. | During hospitalization, 21 patients out of 40 (52%) died. Seven patients presented complications such as right heart ischemia or necropathy (three patients) and a nonfunctional Impella device needing substitution (four patients). | Patients with CS who need short-term cardiac mechanical support may find success with axillary Impella therapy. |
The effect of the Impella device on patients with CS from various etiologies is covered in this section. This includes results, timing, route accessibility, and difficulties. A diagnosis of CS is based on SBP <90 mmHg for more than 30 minutes, supportive therapy to maintain SBP above 90 mmHg, and signs of end-organ damage (altered mental status, decreased urine output, or cold extremities) [3]. Numerous articles published in recent years have shown that the use of the Impella device on patients experiencing cardiogenic shock leads to better results. The studies evaluated in this systematic review showed multiple aspects and outcomes regarding the use of Impella devices. The well-established benefits revealed the improvement of cardiac function and systemic circulation and decreased the severity of the illnesses.

**Outcomes**

In studies conducted on patients with CS treated with the Impella device, gender was initially the first variable examined, and after the analysis of the results, it was determined that there was no difference between males and females in terms of the outcomes [15]. The improvement in cardiac function was perceived after using the Impella device in these patients. However, before this device was implanted, risk factors, such as age and lactate levels, had to be considered before deciding the management [9].

Different scenarios, including mitral valve regurgitation (MVR), Takotsubo syndrome, pulmonary embolism (PE), out-of-hospital cardiac arrest, severe aortic stenosis, valvular disorders associated with ischemia, biventricular failure, ischemic and non-ischemic CS, acute myocardial infarction (AMI), and percutaneous coronary intervention in high-risk patients, could be complicated with CS, but the benefits of this device were higher in all circumstances [11-13,16,17,26,28,31,32,35]. These studies also demonstrated the efficacy of cardiac mechanical support by the Impella device, improving survival and becoming an important tool to manage CS despite the etiology. During hospitalization decision-making by physicians regarding cardiac mechanical support, there was a 2.5-fold increase in the placement of microaxial left ventricular assisting devices (4.1%-9.8%) compared to a reduction in IABP (34.8%-30.0%) between 2015 and 2017. Consequently, it is a significant trend nowadays [14].

The Impella device has been demonstrated to enhance coronary microcirculation by emptying the left ventricular chamber, which contributes to a decrease in endocardial pressure and, as a result, lower coronary circulation resistance, resulting in favorable filling within the microcirculation. During coronary angiography, PressureWire was used to evaluate this finding; later, cardiac magnetic resonance imaging demonstrated no myocardial damage, confirming this statement [20]. Pieri et al. compared patients treated with the Impella device to IABP, measuring cardiac enzymes. The Impella device showed an inferior peak of troponins and creatine phosphokinase compared to IABP; furthermore, at six months, the left ventricular ejection fraction was 45% and 50%, respectively, proving minor muscle injury and the recovery of left ventricular function and systemic circulation and decreased the severity of the illnesses.

**Timing**

The factor ‘time’ must be deliberately selected. In a comprehensive review and meta-analysis, Impella was used as a tool before percutaneous coronary intervention, demonstrating no cardiac arrest and having a positive impact on survival rate. Nevertheless, at 30 days, the mortality rate for CS patients remained high [23]. In a study conducted in Arizona, 262 high-risk patients had the implantation of Impella devices, which were later analyzed. The main finding was a significant difference in the outcomes related to ‘time.’
came to the conclusion that ‘prompt positioning’ seemed to have better results than ‘belated positioning’ in terms of in-hospitalization and one-year all-cause death rates [27].

In another article, Meraj et al. discussed that prior to percutaneous coronary intervention, the implantation of the Impella 2.5 had an improvement in survival compared to post-percutaneous coronary intervention, shown by the Kaplan-Meier curve at 30 days (12.5% versus 48.8%) [30].

**Route of access**

Peripheral access can be challenging in a hospital setting, especially in patients with the diagnosis of CS. Therefore, it is important to mention that in this instance, the use of transcaval emergency mechanical cardiac support Impella 5.0 implantation was successful [6]. Axillary artery access has also shown effectiveness in patients with an aorto-iliac approach [21]. Another analysis was made when the axillary Impella was implanted in patients who needed temporary cardiac support, demonstrating better results [36]. Hence, in these cases, such routes of access can be feasible to consider.

**Complications**

Bleeding was the most common adverse effect during the use of Impella devices [8]. Oezkur et al. found that 53.3% of the patients had coagulation issues, specifically related to acquired von Willebrand syndrome, despite being treated with heparin to maintain a normal activated partial thromboplastin time range. In this situation, the anticoagulation factor should be considered in patients with Impella placement and should be monitored during its use [35]. The phenomenon of acquired von Willebrand disease is common; thus, assessing high-risk patients is a crucial component to prevent bleeding as a complication [18]. According to Goldfarb et al., the loss of high-molecular-weight multimers is a key factor in the diagnosis of acquired von Willebrand syndrome. Blood tests to identify von Willebrand factor activity, fibrinogen, factor VIII, or von Willebrand factor antigen were required in 10 cases where bleeding (mucosal hemorrhage or low hemoglobin) was detected. These patients with these findings also showed high, normal, or elevated levels of ‘low-molecular-weight multimers.’ Due to these findings, type II von Willebrand syndrome (qualitative deficiency) has been recognized. As a result, future intraoperative placement of similar devices, heart transplants, or operations while receiving mechanical cardiac support could all have implications [19]. In a study conducted in a tertiary care facility, renal dysfunction was found to be a common adverse effect in patients with cardiogenic shock and high-risk percutaneous coronary intervention. In another one, hemolysis was also reported as a side effect of the application of biventricular Impella (BiPella) in patients with biventricular failure [22,26]. According to Tarabichi et al., seven out of 21 patients experienced complications such as arm ischemia (axillary access), neuropathy, or Impella device malfunction [36].

Twelve patients with AMI and CS were included in a prospective randomized trial; unfavorable outcomes were also presented and reported; these findings were related to the placement of an Impella in combination with IABP and inotropes, showing no significant changes in left ventricular end-diastolic pressure at one month and being deemed ‘harmful’ by bleeding complications [8]. Despite the theory of hemodynamic improvement using this device, the use of Impella device in CS remains poor in some cases [22]. All of these findings and outcomes may be crucial in the development of new devices and new strategies for the treatment of patients with CS.

Given those mentioned above, in the majority of the studies, the Impella device has been shown to improve the outcomes in patients with CS caused by various etiologies. Nevertheless, it is essential to consider each patient separately because each of them has unique characteristics that may have an impact on the final result, inside and outside of the hospital. When it comes to timing, complications, and access routes, it is indeed critical to learn from errors and use new techniques if problems appear during the treatment. It is also important to develop similar tools such as in the DanGer Shock trial, which was demonstrated to be the first designed powered randomized trial, which determined that mechanical cardiac support with Impella device positioning can increase the expectancy of life in patients suffering from AMI associated with CS [37]. In this manner, we could address and refine patient decisions with advanced criteria depending on the case.

**Limitations**

Our systematic review revealed some limitations. First, only English-language studies from three databases between 2017 and 2022 were included in this study. Second, different study types, such as observational, randomized clinical trials, systematic reviews, and meta-analyses, were selected; as a result, there are variations in the samples and statistical methods, making our revision susceptible to bias. Third, due to the high complexity of the disease and the use of mechanical cardiac support, some studies were conducted with small samples, and finally, the total follow-up was variable in different studies. In this scenario, it is important to highlight that studies with larger samples are desirable to get more conclusive results in order to assure the presence of significant benefits among these patients and later on have a better understanding of the complications.

**Conclusions**

We concluded, based on the information collected, that most patients with a diagnosis of CS have an
improvement using the Impella device. This evaluation was founded on the left ventricular ejection fraction, improvement in the CS criteria signs and symptoms, and favorable response in the follow-ups. There are feasible alternatives by other access routes with the same benefit when patients present difficult access during device implantation by a conventional route. The Impella device may also improve patient outcomes when it comes to timing, a crucial consideration in decision-making. Although any patient could experience an adverse event, it is essential to evaluate and treat each patient distinctively based on their characteristics. We corroborated that the use of this device in these kinds of patients would be widely useful during cardiac support to improve their management and prognosis. Future recommendations include leading and piloting more studies, especially cohorts and randomized controlled trials with larger samples, combinations of therapies, longer follow-up times, and monitoring of complications. These ideas are mentioned in order to gain a clear view of the results after employing this device on CS and perhaps fill some gaps and discrepancies found during this systematic review. Therefore, it is important to mention that more investigation regarding the Impella device is needed to refine and elaborate future evidence.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

I would like to thank all my colleagues with whom I had the opportunity to work during this project and give special thanks to my parents and family for their support every time.

References

1. van Diepen S, Katz JN, Albert NM, et al.: Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017, 136:e232-68. 10.1161/CIR.0000000000000525
2. de Assa I, Rosenberg A: On the right side of the heart: medical and mechanical support of the failing right ventricle. J Intensive Care Soc. 2017, 18:115-20. 10.1177/1721143716684557
3. Bellumkonda L, Gul B, Masri SC: Evolving concepts in diagnosis and management of cardiogenic shock. Am J Cardiol. 2018, 122:1104-10. 10.1016/j.amjcard.2018.05.040
4. Mandawat A, Rao SV: Percutaneous mechanical circulatory support devices in cardiogenic shock. Circ Cardiovasc Interv. 2017, 10:e004357. 10.1161/CIRCINTERVENTIONS.116.004357
5. Puyimurat E, Fagon JY, Aegerter P, et al.: Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012. Eur J Heart Fail. 2017, 19:192-200. 10.1002/ejhf.646
6. Afana M, Alzawil M, Baizir M, et al.: Transcaval access for the emergency delivery of 5.0 liters per minute mechanical circulatory support in cardiogenic shock. Catheter Cardiovasc Interv. 2021, 97:555-64. 10.1002/ccd.29235
7. Rohm CL, Gadidov B, Leitson M, Ray HE, Prasad R: Predictors of mortality and outcomes of acute severe cardiogenic shock treated with the Impella device. Am J Cardiol. 2019, 124:499-504. 10.1016/j.amjcard.2019.05.029
8. Bochaton T, Hurt L, Elbar M, et al.: Mechanical circulatory support with the Impella® LPS-0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: the IMPELLA-STIC randomized study. Arch Cardiovasc Dis. 2020, 113:237-43. 10.1016/j.acvd.2019.10.005
9. Abdullah KQ, Roedler C, Vom Dahl J, et al.: Impella use in real-world cardiogenic shock patients: sobering outcomes. PLoS One. 2021, 16:e0247667. 10.1371/journal.pone.0247667
10. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71
11. Ashraf S, Ando T, Blank N, Munir A, Schreiber T: MitraClip to treat severe ischemic mitral regurgitation during Impella CP support in a 70-year-old woman. Tex Heart Inst J. 2020, 47:306-10. 10.14503/THIJ-18-6901
12. Attisano T, Silviero A, Prota C, Briguori C, Galasso G, Citro R: Impella in Takotsubo syndrome complicated by left ventricular outflow tract obstruction and severe mitral regurgitation. ESC Heart Fail. 2020, 7:306-10. 10.1002/ehj2.12546
13. Buzzotta F, Russo G, Ribichini F, et al.: Long-term outcomes of extent of revascularization in complex high risk and indicated patients undergoing Impella-protected percutaneous coronary intervention: report from the Roma-Verona registry. J Interv Cardiol. 2019, 2019:5249315. 10.1155/2019/5249315
14. Dhruva SS, Ross JS, Mortazavi B: et al.: Use of mechanical circulatory support devices among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA Netw Open. 2021, 4:e2037748. 10.1001/jamanetworkopen.2020.37748
15. Doshi R, Patel K, Dextor D, Jauhar R, Meraj P: Gender disparities with the use of percutaneous left ventricular assist device in patients undergoing percutaneous coronary intervention complicated by cardiogenic shock: from pVAD Working Group. Indian Heart J. 2018, 70 Suppl 1:S90-5. 10.1016/j.ijh.2018.04.009
16. Elder M, Blank N, Kaki A, et al.: Mechanical circulatory support for acute right ventricular failure in the
setting of pulmonary embolism. J Interv Cardiol. 2018, 31:518-24. 10.1111/joic.12505
17. Ellert J, Jensen MJ, Jensen LO, Møller JE: Percutaneous biventricular cardiac assist device in cardiogenic shock and refractory cardiac arrest. EuroIntervention. 2018, 13:e2114-5. 10.4246/EIJ-D-17-00657
18. Flierl U, Tongers J, Berliner D, et al.: Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS One. 2017, 12:e0181593. 10.1371/journal.pone.0181593
19. Goldfarb M, Czer LS, Lam LD, Moriguchi J, Arabia FA, Volod O: High molecular weight von Willebrand factor multimer loss and bleeding in patients with short-term mechanical circulatory support devices: a case series. J Extra Corpor Technol. 2018, 50:77-82.
20. Hamanaka Y, Sotomi Y, Kobayashi T, Hayashi T, Hirayama A, Hirata A, Hijguchi Y: Dynamic change of coronary microcirculation during cardiocirculatory support by the Impella. JACC Cardiovasc Interv. 2020, 13:155-7. 10.1016/j.jcin.2019.08.047
21. Hasegawa T, Tachihana T, Kimura H, Yasaki Y: Successful treatment of refractory cardiogenic shock and electrical storm using the Impella 5.0 with atrial override pacing, in a patient with severe peripheral arterial disease. Int Heart J. 2021, 62:677-81. 10.1536/ihj.20-487
22. Hritani AW, Wani AS, Olet S, Lauterbach CJ, Allahqahand SQ, Bajea T, Ian MF: Secular trend in the use and implementation of Impella in high-risk percutaneous coronary intervention and cardiogenic shock: a real-world experience. J Invasive Cardiol. 2019, 31:265-70.
23. Iannaccone M, Albani S, Giannini F, et al.: Short term outcomes of Impella in cardiogenic shock: a review and meta-analysis of observational studies. Int J Cardiol. 2021, 324:44-51. 10.1016/j.ijcard.2020.09.044
24. Karatolios K, Chatzis G, Luesebrink U, Markus B, Ahrens H, Toussoulis D, Schieffer B: Impella support following emergency percutaneous balloon aortic valvuloplasty in patients with severe aortic valve stenosis and cardiogenic shock. Hellenic J Cardiol. 2019, 60:178-81. 10.1016/j.hjca.2018.02.008
25. Karatolios K, Chatzis G, Markus B, et al.: Comparison of mechanical circulatory support with venoarterial extracorporeal membrane oxygenation or Impella for patients with cardiogenic shock: a propensity-matched analysis. Clin Res Cardiol. 2021, 110:1404-11. 10.1002/crci.20177-9
26. Kuchibhotla S, Esposito ML, Breton G, et al.: Acute biventricular mechanical circulatory support for cardiogenic shock. J Am Heart Assoc. 2017, 6:e006670. 10.1161/JAHA.117.006670
27. Laskani M, Murarka S, Kobayashi A, Seibolt L, Yang T, Pershad A: A retrospective analysis of Impella use in all-romers: 1-year outcomes. J Interv Cardiol. 2017, 30:577-83. 10.1111/joic.12409
28. Manic F, Salinger T, Anders F, et al.: Impella CP use in patients with non-ischaemic cardiogenic shock. ESC Heart Fail. 2019, 6:863-6. 10.1002/ehf2.12446
29. Markus B, Patasialis N, Chatzis G, Luesebrink U, Ahrens H, Schieffer B, Karatolios K: Impact of microaxillar mechanical left ventricular support on renal resistive index in patients with cardiogenic shock after myocardial infarction: a pilot trial to predict renal organ dysfunction in cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2020, 9:158-65. 10.1017/100672619860218
30. Meraj PM, Doshi R, Schreiber T, Maini B, O’Neill WW: Early impact of the axillary Impella 5.0 device on patients with cardiogenic shock and refractory cardiac arrest. J Interv Cardiol. 2019, 32:457-63. 10.1111/jic.12377
31. Nakamura M, Hori M, Nakagaito M, et al.: A case of cardiogenic shock due to acute coronary syndrome successfully recovered by percutaneous and paracorporeal left ventricular assist device. J Artif Organs. 2019, 22:49-52. 10.1002/joa.21-299
32. Nishikawa R, Nagano N, Kobu N, et al.: Favorable effects of Impella on Takotsubo syndrome complicated with cardiogenic shock. Int Heart J. 2021, 62:1430-5. 10.1536/ihj.21-299
33. Oezkur M, Reda S, Rühl H, et al.: Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices. Sci Rep. 2021, 11:23722. 10.1038/s41598-021-02853-8
34. Pappalardo F, Schulte C, Pieri M, et al.: Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017, 19:409-12. 10.1002/ejhf.668
35. Pieri M, Sorrentino T, Oppizzi M, et al.: The role of different mechanical circulatory support devices and their timing of implantation on myocardial damage and mid-term recovery in acute myocardial infarction related cardiogenic shock. J Interv Cardiol. 2018, 31:717-24. 10.1111/jic.12569
36. Tarabichi S, Isegami H, Russo MJ, Lee LY, Lemaire A: The role of the axillary Impella 5.0 device on patients with acute cardiogenic shock. J Cardiothorac Surg. 2020, 15:218. 10.1186/s13019-020-01251-7
37. Udesen NJ, Møller JE, Lindholm MG, et al.: Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J. 2019, 214:60-8. 10.1016/j.ahj.2019.04.019